BACKGROUND AND OBJECTIVES: Residual kidney function in dialysis patients is associated with better survival, but there are no simple methods for its assessment. β-Trace protein is a novel endogenous filtration marker of kidney function that is not removed during hemodialysis and may serve as a marker for residual kidney function similar to serum creatinine in patients not on dialysis. The objective of this study was to determine the association of serum β-trace protein with mortality in incident hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum β-trace protein was measured in baseline samples from 503 participants of a national prospective cohort study of incident dialysis patients with enrollment during 1995-1998 and follow-up until 2004. Outcomes were all-cause and cardiovascular disease mortality analyzed using Cox regression adjusted for demographic, clinical, and treatment factors. RESULTS: Serum β-trace protein levels were higher in individuals with no urine output compared with individuals with urine output (9.0±3.5 versus 7.6±3.1 mg/L; P<0.001). There were 321 deaths (159 deaths from cardiovascular disease) during follow-up (median=3.3 years). Higher β-trace protein levels were associated with higher risk of mortality. The adjusted hazard ratio and 95% confidence interval for all-cause mortality per doubling of serum β-trace protein was 1.36 (1.09-1.69). The adjusted hazard ratios (95% confidence intervals) for all-cause mortality in the middle and highest tertiles compared with the lowest tertile were 0.95 (0.69-1.32) and 1.72 (1.25-2.37). Similar results were noted for cardiovascular disease mortality. CONCLUSIONS: The serum level of β-trace protein is an independent predictor of death and cardiovascular disease mortality in incident hemodialysis patients.
BACKGROUND AND OBJECTIVES: Residual kidney function in dialysis patients is associated with better survival, but there are no simple methods for its assessment. β-Trace protein is a novel endogenous filtration marker of kidney function that is not removed during hemodialysis and may serve as a marker for residual kidney function similar to serum creatinine in patients not on dialysis. The objective of this study was to determine the association of serum β-trace protein with mortality in incident hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum β-trace protein was measured in baseline samples from 503 participants of a national prospective cohort study of incident dialysis patients with enrollment during 1995-1998 and follow-up until 2004. Outcomes were all-cause and cardiovascular disease mortality analyzed using Cox regression adjusted for demographic, clinical, and treatment factors. RESULTS: Serum β-trace protein levels were higher in individuals with no urine output compared with individuals with urine output (9.0±3.5 versus 7.6±3.1 mg/L; P<0.001). There were 321 deaths (159 deaths from cardiovascular disease) during follow-up (median=3.3 years). Higher β-trace protein levels were associated with higher risk of mortality. The adjusted hazard ratio and 95% confidence interval for all-cause mortality per doubling of serum β-trace protein was 1.36 (1.09-1.69). The adjusted hazard ratios (95% confidence intervals) for all-cause mortality in the middle and highest tertiles compared with the lowest tertile were 0.95 (0.69-1.32) and 1.72 (1.25-2.37). Similar results were noted for cardiovascular disease mortality. CONCLUSIONS: The serum level of β-trace protein is an independent predictor of death and cardiovascular disease mortality in incident hemodialysis patients.
Authors: J Craig Longenecker; Michael J Klag; Santica M Marcovina; Yong-Mei Liu; Bernard G Jaar; Neil R Powe; Nancy E Fink; Andrew S Levey; Josef Coresh Journal: J Am Soc Nephrol Date: 2005-03-30 Impact factor: 10.121
Authors: Y Eguchi; N Eguchi; H Oda; K Seiki; Y Kijima; Y Matsu-ura; Y Urade; O Hayaishi Journal: Proc Natl Acad Sci U S A Date: 1997-12-23 Impact factor: 11.205
Authors: R Maiorca; G Brunori; R Zubani; G C Cancarini; L Manili; C Camerini; E Movilli; A Pola; G d'Avolio; U Gelatti Journal: Nephrol Dial Transplant Date: 1995-12 Impact factor: 5.992
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Meredith C Foster; Lesley A Inker; Chi-Yuan Hsu; John H Eckfeldt; Andrew S Levey; Meda E Pavkov; Bryan D Myers; Peter H Bennett; Paul L Kimmel; Ramachandran S Vasan; Josef Coresh; Robert G Nelson Journal: Am J Kidney Dis Date: 2015-03-12 Impact factor: 8.860
Authors: Baohai Shao; Ian de Boer; Chongren Tang; Philip S Mayer; Leila Zelnick; Maryam Afkarian; Jay W Heinecke; Jonathan Himmelfarb Journal: J Proteome Res Date: 2015-06-15 Impact factor: 4.466
Authors: Meredith C Foster; Josef Coresh; Chi-Yuan Hsu; Dawei Xie; Andrew S Levey; Robert G Nelson; John H Eckfeldt; Ramachandran S Vasan; Paul L Kimmel; Jeffrey Schelling; Michael Simonson; James H Sondheimer; Amanda Hyre Anderson; Sanjeev Akkina; Harold I Feldman; John W Kusek; Akinlolu O Ojo; Lesley A Inker Journal: Am J Kidney Dis Date: 2016-03-03 Impact factor: 8.860
Authors: Meredith C Foster; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; John Eckfeldt; Stephen P Juraschek; Josef Coresh Journal: Am J Kidney Dis Date: 2013-03-19 Impact factor: 8.860
Authors: Michael V Rocco; Arlene Chapman; Glenn M Chertow; Debbie Cohen; Jing Chen; Jeffrey A Cutler; Matthew J Diamond; Barry I Freedman; Amret Hawfield; Eric Judd; Anthony A Killeen; Kent Kirchner; Cora E Lewis; Nicholas M Pajewski; Barry M Wall; Jerry Yee Journal: Am J Nephrol Date: 2016-08-12 Impact factor: 3.754
Authors: Philipp Lutz; Rainer Peter Woitas; Sebastian Schwab; Carola Ellen Kleine; Dominik Bös; Sylvie Bohmann; Christian P Strassburg Journal: BMC Nephrol Date: 2021-03-11 Impact factor: 2.388